Clinical trials
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease clinical trials
Below are recruiting mild cognitive impairment (mci) due to alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 57 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06889818Recruiting
Alzheimer's treatment and diagnostics registry study
This study creates a registry for people who are using newly approved Alzheimer's medications. It tracks how these treatments work over time and may help researchers learn more about diagnosing and treating Alzheimer's.
IncheonAges 19 years+ - NCT06902181Recruiting
Inhaling an essential oil for mild memory loss
This trial tests whether inhaling a special essential oil (CXMCI-01) can help people with mild cognitive impairment (MCI) — a condition where you have more memory problems than normal for your age. The study aims to see if the oil is safe and might improve memory and thinking.
TaichungAges 50 years+ - NCT07027072RecruitingPhase 2
Testing KDS2010 for early Alzheimer's memory loss
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Gwangju, GwangjuAges 50–85 - NCT07089303Recruiting
Alzheimer's brain imaging study (AD-MINER)
This study uses advanced brain imaging to learn more about Alzheimer's disease. It looks at people with normal memory, mild memory problems, or Alzheimer's dementia to find better ways to diagnose and track the disease.
Beijing, Beijing MunicipalityAges 55–90 - NCT07383311Recruiting
Memory, sleep, and a natural supplement
This trial tests whether a natural substance (from wheat germ) that boosts a process called autophagy can help improve sleep in people who are worried about their memory or have mild memory problems but do not have dementia.
Greifswald, Mecklenburg-VorpommernAges 55–70 - NCT07672977Enrolling by invitation
Sound therapy at home to improve deep sleep in early Alzheimer's
This study tests whether a wearable device that plays soft sounds during sleep can boost deep sleep brain waves in people with mild memory problems caused by Alzheimer's. It aims to see if this simple, home-based approach can help protect memory and thinking.
Zaragoza, ZaragozaAges 50–75 - NCT07512362RecruitingPhase 2
Stem cells and antibodies for early Alzheimer's disease
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
Miami, FloridaAges 55–90 - NCT07553338RecruitingPhase 2
Leronlimab Safety and Brain Inflammation in Alzheimer's
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
New York, New YorkAges 50 years+ - NCT07643363Recruiting
Brain Stimulation for Cognitive Impairment in Dementia
This study tests a new brain stimulation technique called temporal interference stimulation to help slow cognitive decline in people with Alzheimer's disease or frontotemporal dementia. Researchers will combine this stimulation with cognitive training to see if it improves memory and thinking skills.
Tianjin, Tianjin MunicipalityAges 45–85 - NCT07667478Recruiting
Brain stimulation study for early Alzheimer's memory loss
This study tests whether a non-invasive magnetic brain stimulation technique can help improve memory in people with early Alzheimer's disease. It may be an option if you have mild cognitive impairment or mild dementia due to Alzheimer's and have had a positive blood test for Alzheimer's markers.
Houston, TexasAges 55–90 - NCT07287852Enrolling by invitationPhase 2
Ginkgo biloba extract for mild cognitive impairment
This trial tests whether a specific ginkgo biloba extract (EGb761) can improve thinking and memory in people with mild cognitive impairment (MCI). It also looks at changes in blood markers related to the condition.
JerusalemAges 65 years+ - NCT06379594Enrolling by invitation
Remote brain health clinic for mild memory problems
This study tests a remote 'brain health clinic' for people with mild memory or thinking problems (mild cognitive impairment). It aims to help diagnose the cause of memory issues from home, so you don't need to travel to a clinic.
London, Denmark HillAges 18 years+ - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT05456503RecruitingPhase 3
PET scan study of tau buildup in memory and brain disorders
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07392723RecruitingPhase 2
Flaxseed nutrition to protect memory in APOE4 adults
This study tests a special flaxseed-based nutrition drink to see if it can slow memory loss in older adults who have the APOE4 gene and mild cognitive impairment (early memory trouble). If you qualify, you'll take the drink daily for a year and have memory tests and brain scans.
New Brunswick, New JerseyAges 60 years+ - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT06775964RecruitingPhase 1/Phase 2
Stem cell therapy for early Alzheimer's disease
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Houston, TexasAges 60–80
Hear when a new Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild cognitive impairment (mci) due to alzheimer's disease?
- Yes. Clin2 currently lists 57 recruiting mild cognitive impairment (mci) due to alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild cognitive impairment (mci) due to alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild cognitive impairment (mci) due to alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.